2001PubMedRequires access

[Treatment of deep vein thrombosis. Current and future questions].

J.N. Fiessinger

Open publisher page 0 citations

Abstract

Treatment of deep vein thrombosis is founded on the association of low molecular weight heparin and oral anticoagulant for three or six months. However efficacy and safety of low molecular weight heparin are not different from that of unfractionated heparin. Moreover measurement of anti-Xa activity does not permit a clear definition of therapeutic range in patients with a high hemorrhagic risk. Oral anticoagulant prevent recurrences of venous thrombosis, however the high risk of major haemorrhages limits their long term use. Pentasaccharide and Melagatran are news potent drugs that should deeply modify the treatment of venous thrombo-embolism.

About this research paper

What this paper is about

Treatment of deep vein thrombosis is founded on the association of low molecular weight heparin and oral anticoagulant for three or six months. However efficacy and safety of low molecular weight heparin are not different from that of unfractionated heparin. Moreover measurement of anti-Xa activity does not permit a clear definition of therapeutic range in patients with a high hemorrhagic risk. Oral anticoagulant prevent recurrences of venous thrombosis, however the high risk of major haemorrhages limits their long term use. Pentasaccharide and Melagatran are news potent drugs that should deeply modify the treatment of venous thrombo-embolism.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Treatment of deep vein thrombosis is founded on the association of low molecular weight heparin and oral anticoagulant for three or six months. However efficacy and safety of low molecular weight heparin are not different from that of unfractionated heparin. Moreover measurement of anti-Xa activity does not permit a clear definition of therapeutic range in patients with a high hemorrhagic risk. Oral anticoagulant prevent recurrences of venous thrombosis, however the high risk of major haemorrhages limits their long term use. Pentasaccharide and Melagatran are news potent drugs that should deeply modify the treatment of venous thrombo-embolism.

Key concepts: Deep vein, Medicine, Heparin, Thrombosis, Anticoagulant, Venous thrombosis, Low molecular weight heparin, Therapeutic index

Related papers

Back to paper searchBrowse research topicsOriginal source
[Treatment of deep vein thrombosis. Current and future questions]. — Research Paper | ScholarLens